BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Presenting Nintendo's New Pastel Bliss Con Tones for Switch Gamers: 3 Smart Choices- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- Phonetic Associations: A Survey of \Interfacing Worldwide People group\ Language Trade Application
- 6 Robot Vacuum Cleaners for Easy Home Cleaning
- 6 Web-based Lawful Administrations: Extensive Surveys and Elements
- 'Seditious behavior': Trump accuses Democrats who made video reminding the military not to follow illegal orders of a crime — but is it?
- Wonderful Sea shores All over the Planet
- Was This Driver Simply Having A great time Or Behaving Like An Ass?
- Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
